AYTU BIOPHARMA, INC Deferred State and Local Income Tax Expense (Benefit)
AYTU BIOPHARMA, INC (AYTU) reported Deferred State and Local Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2024-09-26
- AYTU BIOPHARMA, INC deferred state and local income tax expense (benefit) for fiscal 2024 was $0.00.
- AYTU BIOPHARMA, INC deferred state and local income tax expense (benefit) for fiscal 2023 was -$17.00K.
- AYTU BIOPHARMA, INC deferred state and local income tax expense (benefit) for fiscal 2022 was -$26.00K, a 160.47% decline from fiscal 2021.
- AYTU BIOPHARMA, INC deferred state and local income tax expense (benefit) for fiscal 2021 was $43.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-06-30 | $0.00 10-K · filed 2024-09-26 |
| 2023-06-30 | -$17.00K 10-K · filed 2024-09-26 |
| 2022-06-30 | -$26.00K 10-K · filed 2023-10-12 |
| 2021-06-30 | $43.00K 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |